Relievant Medsystems
Relievant Medsystems developed and commercialized the Intracept Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain (CLBP). Over five millions Americans experience vertebrogenic CLBP, many of whom do not achieve lasting results after years of cycling through various courses of care. Intracept has shown improvements in both pain and function through two Level I randomised controlled trials and long-term outcomes data. The company was headquarted in Minneapolis, MN (US) and was acquried by Boston Scientific (NYSE: BSX) in 2024.